Skip to main content
Erschienen in: Reactions Weekly 1/2024

01.02.2024 | Case report

Secukinumab

Verruca vulgaris

Erschienen in: Reactions Weekly | Ausgabe 1/2024

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Mahajan R, et al. Case report: Interleukin-17 targeted biological therapy in netherton syndrome. Frontiers in Pediatrics 11: 1-5, Jan 2023. Available from: URL: https://dx.doi.org/10.3389/fped.2023.1297658 Mahajan R, et al. Case report: Interleukin-17 targeted biological therapy in netherton syndrome. Frontiers in Pediatrics 11: 1-5, Jan 2023. Available from: URL: https://​dx.​doi.​org/​10.​3389/​fped.​2023.​1297658
Metadaten
Titel
Secukinumab
Verruca vulgaris
Publikationsdatum
01.02.2024
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2024
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-024-53249-9

Weitere Artikel der Ausgabe 1/2024

Reactions Weekly 1/2024 Zur Ausgabe

Case report

Sodium-valproate

Case report

Multiple drugs

Case report

Multiple drugs

Case report

Rivaroxaban